Company Overview

Syros Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for hematologic malignancies and other cancers with high unmet medical need. The company operates within the biotechnology and oncology drug development industries, with its core activities centered on precision medicine, gene regulation science, and molecularly targeted therapeutics. Syros has historically concentrated on identifying and advancing therapies designed to control gene expression and address genetically defined patient populations.

The company’s principal revenue drivers have historically consisted of collaboration revenue, licensing arrangements, and external funding associated with research partnerships, rather than commercial product sales, as it remains primarily a development-stage enterprise. Syros’ lead development programs have included tamibarotene, an oral selective retinoic acid receptor alpha agonist evaluated in acute myeloid leukemia and myelodysplastic syndromes, and SY-2101, an oral arsenic trioxide formulation. Founded in 2011 and headquartered in Cambridge, Massachusetts, the company evolved from an epigenetics and gene-control research platform into a focused oncology therapeutics developer emphasizing biomarker-driven clinical programs.

Business Operations

Syros conducts its operations primarily through research and clinical development activities in oncology. Its business model has centered on advancing proprietary drug candidates through clinical trials while leveraging scientific expertise in transcriptional regulation and genomics. The company’s operational focus has largely been concentrated within the United States, although clinical trial activities and investigator relationships have included international sites and collaborators. Revenue generation has historically depended on partnership agreements, milestone payments, licensing activities, and financing transactions tied to the advancement of its therapeutic pipeline.

The company has controlled intellectual property related to gene-control technologies, targeted oncology compounds, and associated biomarkers. Syros has previously entered strategic collaborations with larger pharmaceutical organizations and academic institutions to support research and development efforts. Its pipeline development activities have relied on contract research organizations, manufacturing partners, and clinical trial networks rather than large-scale internal manufacturing infrastructure. Public filings have identified programs and assets associated with precision oncology approaches, particularly in genetically defined blood cancers.

Strategic Position & Investments

Syros’ strategic direction has focused on advancing precision medicines for hematologic malignancies using biomarker-based patient selection and targeted therapeutic mechanisms. The company has invested heavily in clinical-stage oncology programs, especially tamibarotene and SY-2101, with the objective of addressing molecularly defined subsets of leukemia and related disorders. Strategic priorities have included clinical trial execution, regulatory engagement, and the expansion of intellectual property supporting targeted oncology therapies.

The company has also pursued external collaborations and financing arrangements to support ongoing development activities and operational liquidity. Syros previously broadened its oncology portfolio through acquisitions and licensing activities, including the acquisition of Tyme Technologies, Inc., which expanded its clinical-stage asset base. Its broader strategic positioning has emphasized differentiated therapies for underserved cancer populations rather than broad primary-care pharmaceutical markets. Data regarding long-term commercialization strategy beyond currently disclosed clinical programs remains limited in public filings, and some future operational direction remains dependent on financing and clinical outcomes.

Geographic Footprint

Syros Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts, within the biotechnology hub of the greater Boston area. Its operational footprint has primarily been concentrated in the United States, where corporate management, research oversight, and most administrative activities are based. The company has participated in multicenter clinical studies involving both domestic and international institutions to support oncology drug development programs.

Although Syros does not maintain the broad commercial infrastructure of a multinational pharmaceutical company, its clinical development activities have involved relationships across North America, parts of Europe, and select global research networks. The company’s international exposure has primarily stemmed from clinical operations, regulatory engagement, scientific collaboration, and outsourced development partnerships rather than direct commercial sales operations.

Leadership & Governance

Syros was founded by scientists and biotechnology executives involved in the study of gene regulation and epigenetics, with the company developing under a governance model typical of publicly traded clinical-stage biotechnology firms. Strategic leadership has emphasized precision oncology, disciplined pipeline prioritization, and targeted development in genetically defined cancers. The company’s board and executive leadership have included experienced biotechnology, pharmaceutical, and financial executives with backgrounds in oncology drug development and capital markets.

Key executives identified in public corporate disclosures have included:

• Nancy Simonian, M.D. – Chief Executive Officer
• Michael A. Metzger – President and Chief Financial Officer
• Eric Olson – Chief Business Officer
• David A. Roth, M.D. – Chief Medical Officer
• Amit Rakhit, M.D., MBA – Former President and Chief Executive Officer

Corporate governance practices have been disclosed through public company reporting, including SEC filings, proxy statements, and investor communications. Leadership strategy has consistently emphasized advancing targeted therapies through clinical validation, regulatory engagement, and capital allocation aligned with oncology pipeline development.